ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

OPTI Optibiotix Health Plc

17.50
0.25 (1.45%)
04 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Optibiotix Health Plc LSE:OPTI London Ordinary Share GB00BP0RTP38 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.25 1.45% 17.50 17.00 18.00 17.50 17.25 17.25 122,391 08:06:20
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Noncomml Resh Organizations 457k 2.59M 0.0284 6.16 15.96M
Optibiotix Health Plc is listed in the Noncomml Resh Organizations sector of the London Stock Exchange with ticker OPTI. The last closing price for Optibiotix Health was 17.25p. Over the last year, Optibiotix Health shares have traded in a share price range of 5.75p to 43.50p.

Optibiotix Health currently has 91,190,661 shares in issue. The market capitalisation of Optibiotix Health is £15.96 million. Optibiotix Health has a price to earnings ratio (PE ratio) of 6.16.

Optibiotix Health Share Discussion Threads

Showing 18176 to 18197 of 147675 messages
Chat Pages: Latest  735  734  733  732  731  730  729  728  727  726  725  724  Older
DateSubjectAuthorDiscuss
22/11/2016
16:36
Email from the Horses mouth Elrico.
john henry
22/11/2016
16:34
I doubt that JH. - More like copyright?
elrico
22/11/2016
16:07
I understand that the reason the Summit presentation has not been posted on the website is due to the fact that it was written for scientists and would probably confuse people. Positive feedback.
john henry
22/11/2016
15:44
JH - unfortunately some will have much needed Christmas funds invested. Its never a smart move to invest what you may need. I imagine they will be disappointed if there is no significant upbeat info with tangible and significant news before Christmas.
elrico
22/11/2016
15:25
Some peeps desperate to get out, taking ever lower prices on virtually zero volume.
john henry
22/11/2016
14:32
Very confident going forward. Expecting a significant uplift over the next 6 months.
rafboy
22/11/2016
14:31
OPTI year end next Wednesday. Might be a good excuse for an update?
someuwin
22/11/2016
14:09
Shush...people are reading :-)
elrico
22/11/2016
13:57
I'm still, still invested - and I do like a nice quiet thread!
silverpete
22/11/2016
01:35
Keep up Brian.
elrico
21/11/2016
22:12
Opti shares trading on the Borse without their knowledge is something to get excited about
briansewell
21/11/2016
16:08
There's nowt to see here or get excited about. Move along please.
investordave
21/11/2016
11:52
Is there a problem with this thread? The last post I can see is 17444 from 18 Nov.
mrcleverdick
18/11/2016
18:14
It's also easier to spike when your market cap us sub 10m
onedayrodders
18/11/2016
13:47
Patience kipper.

OPTI has been working with DSM for quite a while now. Product deals or partner commercial deals could come at any time. Expect a huge percentage gain then.

someuwin
18/11/2016
13:35
This RNS from PXS is not dissimilar to the one OPTI issued to announced the DSM deal; i.e. plenty of talk about the potential market opportunity but no hard commercial numbers - jam tomorrow. And yet the PXS share price jumped 40% on the announcement, whereas OPTI's jump was sweet FA. Strange.
kipper1960
18/11/2016
10:53
Yup - PXS only have one product (A tomato extract).

We have multiple products.

(and we're already partnered with DSM too)

someuwin
18/11/2016
10:50
Yep indeed Someuwin, pretty big news for PXS, partnering with a 2b Chinese MN. Wonder what happenes if OPTI does have a deal with PG - a 200b MN. I drool at the thought of it...One day....
woodaldo
18/11/2016
10:24
Provexis plc (LSE:PXS) interesting news today.

PXS use Tomato extract for their functional food ingredient. This is the sort of announcements we'll be getting from OPTI at some stage - hopefully...

"Provexis plc ("Provexis" or the "Company"), the business that develops, licenses and sells the proprietary, scientifically-proven Fruitflow(R) heart-health functional food ingredient, is pleased to announce that the Company's Alliance partner for Fruitflow(R), DSM Nutritional Products ("DSM"), has entered into a strategic collaboration agreement for Fruitflow(R) with BY-HEALTH Co., Ltd ("BY-HEALTH"), a substantial listed Chinese dietary supplement business.

The strategic collaboration agreement between DSM and BY-HEALTH will focus on the development of new products that contribute to cardiovascular health, to include the establishment of relevant evaluation and testing procedures to accord with Chinese technical and regulatory standards.

The development process will target the creation of new products for people who are at risk of cardiovascular disease, particularly to include those over 40 years of age. There are already more than 230m people in China who are thought to have cardiovascular disease, and a significant increase in cardiovascular events is expected in China over the course of the next decade based on population aging and growth alone.(1) The Company believes that Fruitflow(R) has the potential to play an import role in primary prevention in the Chinese market."

someuwin
17/11/2016
23:40
Totally agree RB1, after reading SOH's email again, it's clear that the plan is for LP-LDL to be an ingredient in numerous products. If it goes into a MN's big seller (or big sellers), we'll be very happy.

It sounds like we could be selling the ingredient to some partners and others will be manufacturing it and presumably, we would receive royalties or some form of licence fee.

I much prefer this route, let the big companies do the marketing and we can reap the rewards.

fozdad
17/11/2016
23:31
I suspect we'll see multiple deals with multiple partners next year. Lpldl will be more like an ingredient rather than a product that can be presented in multiple formulations. This hugely de risks this opportunity within the optiscreen platform increasing the divisions growth prospects through multiple recurring revenue streams. Do this with diabetes, cognitive, bone health etc this division alone will be very lucrative. Point 5 of sohs email gives the perfect explanation to why it's not always best relying on one company and shows his thinking (for the last time - ab life DuPont example once again comes to mind). It's still very much possible opti is sitting on a potential natural statin replacement in this product alone. I would rather the company retain some kind of control.
riskybusiness1
17/11/2016
22:46
Mazz, read post 17433, 2 up from your question, it's in there
fozdad
Chat Pages: Latest  735  734  733  732  731  730  729  728  727  726  725  724  Older